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Fibroblast-specific protein 1 is a specific prognostic marker for
renal survival in patients with IgAN.
Background. There is little direct evidence that fibroblasts are
involved in the progression of the renal interstitial fibrosis in hu-
man glomerulonephritis. With the availability of a new specific
marker for fibroblasts, we determined the presence of fibrob-
lasts in kidneys with IgA nephropathy (IgAN) and correlated
their numbers with various clinical parameters. In particular,
we also prospectively asked if the number of fibroblasts in the
renal interstitium correlates with prognosis.
Methods. Cells positive for fibroblast-specific protein 1
(FSP1) were localized in renal biopsy specimens using immuno-
histochemistry with anti-FSP1 antibody. Clinical features were
analyzed by one-way analysis of variance (ANOVA) with the
Bonferroni correction. To assess the prognostic impact of
the number of FSP1+ fibroblasts on renal survival in 142 pa-
tients with normal serum creatinine, the relationship between
covariates to renal survival were evaluated univariately using
the log-rank test and multivariately using Cox proportional
hazards.
Results. Fibroblasts identified by their expression of FSP1
accumulate in areas showing severe interstitial fibrosis. Some
tubular epithelial cells undergoing epithelial-mesenchymal
transition (EMT) in fibrotic areas also express FSP1. Numbers
of FSP1+ fibroblasts directly correlate with serum creatinine
(r = 0.74, P < 0.0001) and inversely correlate with estimated
creatinine clearance (r = −0.54, P < 0.0001), and by multivari-
ate analysis, the clinical factors influencing renal survival are
urinary protein excretion [≥1.0 g/day, relative risk (RR) = 4.20,
P = 0.032], hypertension (RR 5.85, P = 0.0027), and ≥20 FSP1+
fibroblasts per high power field (HPF) (RR 7.39, P = 0.0015).
Staining for FSP1+ fibroblasts is largely nonoverlapping with
a-smooth muscle actin+ (a-SMA) cells in the interstitium.
1See Editorial by Bruneval, p. 1366.
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Conclusion. The target protein FSP1 identifies human fibrob-
lasts and tubular epithelium undergoing EMT, and distinguishes
them from the diaspora of a-SMA+ vascular smooth muscle
cells. FSP1+ fibroblasts are critically related to the progression
of IgAN; consequently, staining FSP1 in renal biopsy specimens
provides a valuable histologic index of progression.
IgA nephropathy (IgAN) is the most common form
of glomerulonephritis and a major cause of end-stage
renal disease (ESRD) worldwide [1–5]. Ten percent to
40% of IgAN patients progress to dialysis or renal trans-
plantation over 10 to 25 years [3–9]. Of the clinical and
histologic parameters evaluated in various multivariate
analyses, severe proteinuria, hypertension, renal dysfunc-
tion, extent of glomerular lesions, and interstitial fibrosis
appear to be the most important predictors of poor out-
come [6–19]. Some of the patients in those studies how-
ever were without aforementioned risk factors and still
developed renal failure. This observation highlights the
need for stronger predictors of individual outcome fol-
lowing primary glomerulonephritis.
Several morphometric studies suggest that the extent
of tubulointerstitial fibrosis correlates better with re-
duced renal function than glomerular injury [9, 20]. The
extent to which this fibrosis reflects fibroblast number is
unclear because there have been no specific marker for
tissue fibroblasts until recently. Strutz et al [21] cloned
fibroblast-specific protein 1 (FSP1) in mice, an S100A4
protein constitutively expressed in the cytoplasm of tis-
sue fibroblasts, and demonstrated that cells identified by
FSP1 expression rapidly increase in number during ex-
perimental fibrosis. The proximity of these fibroblasts to
the extracellular matrix further suggested they were re-
sponsible for the generation of new matrix proteins [22].
Finally, we recently reported that experimental fibrogen-
esis was attenuated by the selective elimination of tissue
fibroblasts using a herpes virus thymidine kinase trans-
gene under the control of the FSP1 promoter [23]. That
report provided the first direct evidence that fibroblasts
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play a crucial role in the progression of fibrosis in vivo.
This notion has not been tested in the interstitial fibrosis
accompanying human glomerulonephritis. We therefore
analyzed prospectively a group of patients with IgAN
whose serum creatinine concentration was normal at the
time of renal biopsy.
METHODS
Study population
One hundred fifty-three patients (66 males and 87
females) with biopsy-proven IgAN were enrolled in this
study after providing fully informed consent. Patients
with purpura nephritis, lupus erythematosus, diabetes
mellitus, neoplasia, viral hepatitis, or other infections
were excluded. The patients ranged from 13 to 69 years
of age at onset (average 37.7 years), and all presented
with persistent proteinuria, including 19 (12.4%) whose
baseline proteinuria exceeded 3.0 g/day. Eleven patients
(7.2%) who showed renal dysfunction (serum creatinine
≥1.5 mg/dL) at the time of renal biopsy were excluded
from the multivariate analysis. Renal survival was defined
as the duration from renal biopsy to the end point that
was a 100% increase in serum creatinine from baseline. To
assess the relationship between clinical parameters and a
change in renal function, patients were divided into three
groups based on the extent of changes in renal function:
(1) ≥100% increase in serum creatinine from baseline,
(2) 1% to 99% increase, and (3) no increase.
Clinical and histologic parameters
Hypertension was defined as a systolic blood pressure
of greater than 140 mm Hg and a diastolic pressure of
greater than 90 mm Hg. Urine and blood samples col-
lected at the time of renal biopsy (baseline) were analyzed
for serum creatinine, 24-hour total protein excretion, and
creatinine clearance. Serum creatinine was measured and
recorded every 2 months and at the end of each follow-
up year. Renal biopsy specimens that included at least 10
glomeruli were analyzed for the prevalence of glomeru-
losclerosis and the severity of mesangial proliferation.
Mesangial proliferation was defined as four or more nu-
clei in mesangial area and mesangial matrix expansion.
The severity of mesangial proliferation was semiquan-
titatively graded according to the modified method of
a previous report as follows: mild, more than 90% of
glomeruli showing mild mesangial proliferation (occu-
pying less than 30% of glomerular area); and moderate,
more than 50% of glomeruli showing moderate mesan-
gial proliferation (occupying more than 30% of glomeru-
lar area). Glomerulosclerosis was determined as a
percentage of glomeruli showing global sclerosis or seg-
mental sclerosis [24, 25].
Immunoblot analysis
One-dimensional immunoblot analysis was performed
using lysates from ATCC TIB 87 cells (Manassas, VA,
USA) (fibroblast cell line) and various other types of
human cells in primary culture (dermal fibroblasts, epi-
dermal keratinocytes, smooth muscle cells, vascular en-
dothelial cells, mesangial cells, tubular epithelial cells,
and CD45+ lymphocytes). These primary cells except
CD45+ cells were purchased from Dainippon Pharm
(Osaka, Japan). CD45+ cells were isolated from blood us-
ing magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Twenty microgram samples of total cellular
protein were run on 15%/25% gradient sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
gels and transferred to polyvinlydine difluoride (PVDF)
membranes (Bio-Rad, Tokyo, Japan) by electroblotting.
After blocking with 5% nonfat dry milk in phosphate-
buffered saline (PBS), the membrane was incubated with
primary rabbit polyclonal anti-FSP1 antibody (1:5000) or
monoclonal anti-b actin (1:5000) (Sigma-Aldrich, Tokyo,
Japan) and then with a secondary antibody as reporter
[21]. Positive reaction products were identified by chemi-
luminescence.
Morphometric analysis
Deparaffinized sagittal renal cross-sections were
stained with Masson’s trichrome, after which a standard
point counting method was used to quantitate interstitial
collagen deposition [23]. Each of 10 random, nonoverlap-
ping high power fields (HPF) (magnification 400×) was
transferred to the screen of a computer; 10 HPFs cov-
ered more than 70% of the whole section. A total of 2800
points were then evaluated in each kidney using a grid
containing 280 (20 × 14) sampling points. The percent
fractional area of interstitial fibrosis was determined by
taking the number of grid points staining for blue colla-
gen in the interstitium (excluding perivascular areas and
areas within glomeruli or tubules) divided by the total
number of points in the field.
Immunohistochemistry
Renal biopsy specimens were fixed in 10% buffered
formalin for 12 hours, dehydrated, embedded in paraffin,
and sectioned according to standard procedures. After
deparaffinizing the sections, they were incubated with
proteinase K (4 lg/mL) for 30 minutes at room tem-
perature, after which endogenous peroxidase activity
was blocked with 0.3% hydrogen peroxide, and nonspe-
cific protein binding sites were blocked with 5% nor-
mal goat serum in PBS containing 2% bovine serum
albumin (BSA). The sections were then incubated with
primary rabbit polyclonal anti-FSP1 [21] (1:2000) or mon-
oclonal anti-a-smooth muscle actin (a-SMA) antibody
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(1:100) (Sigma-Aldrich, St. Louis, MO, USA) for 12
hours at 4◦C, washed three times in PBS, incubated
with biotinylated secondary antibody, developed using
the ABC-peroxidase method, and counterstained with
hematoxylin [23]. The specificity of FSP1 staining was
determined using control rabbit serum and by absorp-
tion using anti-FSP1 antibody with excess recombinant
FSP1 protein. The number of FSP1+ fibroblasts within
the cortex was counted in each of 10 nonoverlapping
microscope fields (magnification 200×) and then aver-
aged. The positively stained area for a-SMA was calcu-
lated using morphometric analysis as described above.
Morphometry was performed on the same fields using the
serial sections. All of the secondary antibodies were iso-
lated by immunoaffinity chromatography and absorbed
for dual labeling.
Dual staining using paraffin sections
Dual staining using paraffin sections was used to exam-
ine the colocalization of FSP1 and a-SMA or heat shock
protein 47 (HSP47) in fibroblasts. Sections were first
stained with anti-FSP1 antibody (1:2000) as described
above, followed by incubation with monoclonal anti-a-
SMA (1:100) (Sigma-Aldrich) or monoclonal anti-HSP47
(Colligin) (StressGen Biotechnologies Corp., Victoria,
BC, Canada). Before staining with anti-HSP47 antibody,
heating of the section at 95◦C for 10 minutes in 10 mmol/L
sodium citrate buffer (pH 6.0) was performed for anti-
gen unmasking [23]. Sections were sequentially incubated
with the alkaline phosphatase–labeled antimouse IgG
(1:500) (DakoCytomation Co. Ltd., Kyoto, Japan). Al-
kaline phosphatase activity as detected with 5-bromo-4-
chloro-indoxyl phosphate/nitro blue tetrazolium chloride
(BCIP/NBT) (DakoCytomation).
Statistical analysis
Statistical calculations were made with the Statview
system. Renal survival was estimated using Kaplan-Meier
plots. Linear regression analysis was used to assess the
correlation between the number of FSP1+ fibroblasts
and several parameters. Differences in the parameters
of clinical features among the three groups were ana-
lyzed by one-way analysis of variance (ANOVA) with the
Bonferroni correction. To assess the prognostic impact of
the number of FSP1+ fibroblasts on renal survival, the re-
lationship between covariates to renal survival were eval-
uated univariately using the log-rank test and multivari-
ately using the Cox proportional hazards model. Values
of P < 0.05 were considered significant in all analyses.
RESULTS
Localization of FSP1
We initially tested the specificity of our rabbit poly-
clonal anti-FSP1 antibody by carrying out immunoblot
analyses of lysates obtained from various primary hu-
man cell types (Fig. 1A). Fibroblasts expressed FSP1 but
many other cell types, including smooth muscle cells, did
not. That a positive reaction to the antibody was de-
tected exclusively in fibroblasts [21–23] confirmed its fine
specificity for that cell type in humans. Next, the label-
ing of kidney sections with IgAN using anti-FSP1 anti-
body revealed the accumulation of fibroblasts in areas of
the kidney showing severe interstitial fibrosis (FSP1/IgA)
(Fig. 1B); as observed in rodents, only occasional intersti-
tial fibroblasts labeled with anti-FSP1 antibody in normal
human kidney tissue (FSP1/control) (Fig. 1B). Notably,
some tubular epithelial cells surrounding the fibrotic ar-
eas also expressed FSP1, which is indicative of epithelial-
mesenchymal transition (EMT).
In addition, fibrotic areas showed a positive reaction
product for anti-a-SMA antibody; however, the rather
diffuse distribution of a-SMA differed markedly from
that of FSP1. Double staining of kidney sections revealed
that FSP1+ fibroblasts and a-SMA+ cells were typically
nonoverlapping (Fig. 1C); in this representative section
only 10% of FSP1+ cells (18 out of 180 FSP1+ fibrob-
lasts) were also positive for a-SMA. At least 10 tubu-
lar epithelial cells expressed FSP1, but we did not find
any tubular epithelial cells expressing a-SMA. To demon-
strate if FSP1+ fibroblasts were effectors of fibrosis, we
also performed dual labeling using anti-FSP1 antibody
and anti-HSP47 antibody. As shown in Figure 1D, about
70% of FSP1+ fibroblasts (19 out of 28 FSP1+ cells) also
expressed HSP47, identifying collagen type I expressing
cells.
Correlation between number of FSP1+ fibroblasts and
clinical or histologic parameters
To clarify the potential role or involvement of FSP1+
fibroblasts in the progression of IgAN, we examined the
correlation between various clinical and histologic pa-
rameters and the recorded number of FSP1+ fibroblasts.
Among the clinical parameters tested (Table 1), the num-
ber of FSP1+ fibroblasts was positively correlated with
age, urinary excretion of protein, and serum creatinine
(r = 0.74, P < 0.0001), and was inversely correlated with
creatinine clearance (r = −0.54, P < 0.0001). Among
the histologic parameters tested, the number of FSP1+
fibroblasts was positively correlated with glomeruloscle-
rosis and the area of fibrosis (r = 0.80, P < 0.0001).
Clinical features at the time of renal biopsy and the
changes in renal function
Clinical features at the time of renal biopsy in the three
groups are shown in Table 2. Urinary excretion of pro-
tein, serum creatinine, hypertension, a-SMA+ cells, and
FSP1+ cells in the ≥100% increase group were signifi-
cantly higher than that in the 1% to 99% increase group
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Fig. 1. Localization and Western blotting of fibroblast-specific protein 1. (A) Western blotting. FSP1 was detected in TIB 87 (fibroblast cell line)
and primary human dermal fibroblast, but not in epidermal keratinocytes, smooth muscle cells, vascular endothelial cells, mesangial cells, tubular
epithelial cells, and CD45+ cells. (B) Localization of FSP1. FSP1+ cells accumulate in renal areas showing interstitial fibrosis. Some tubular epithelial
cells surrounding the fibrotic areas also expressed FSP1 (arrows). The control section shows very little background staining. (C) The colocalization
of a-smooth muscle actin (a-SMA) with FSP1. Double-stained cells (arrows) were less than 10%. (D) FSP1 and heat shock protein 47 (HSP47)
staining. Double staining of areas of active kidney fibrosis reveal that FSP1 colocalized with HSP47 in most fibroblasts, suggesting most of these
cells express collagen type I.
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Table 1. Correlation of fibroblast-specific protein 1 (FSP1+) cell
number with clinical or histologic parameters
r P value
Clinical parameters
Age 0.27 0.0007
Urinary excretion of protein for 24 hours 0.28 0.0005
Serum creatinine 0.74 <0.0001
Creatinine clearance −0.54 <0.0001
Histological parameters
Glomerulosclerosis 0.55 <0.0001
Area of fibrosis 0.80 <0.0001
a-smooth muscle actin+ area 0.39 <0.0001
and no increase group. Male gender, glomerulosclerosis,
and area of fibrosis in the ≥100% increase group and
the 1% to 99% increase group were significantly greater
than that in no increase group. Creatinine clearance in
the ≥100% increase group and the 1% to 99% increase
group were significantly lower than that in no increase
group.
Risk factors for ESRD
To determine whether the number of FSP1+ fibrob-
lasts correlated with the long-term prognosis of IgAN, we
prospectively analyzed 142 IgAN patients whose serum
creatinine concentrations were normal at the time of
renal biopsy. The follow-up period ranged from 0.6 to
8 years (average 5.6 years), during which a total of 24
patients (16.9%) reached the end point of a doubling in
baseline serum creatinine. Fourteen patients (9.9%) pro-
gressed to ESRD.
The significance of each factor affecting the renal sur-
vival rate is shown in Tables 2 and 3. Among the clinical
parameters, univariate analysis showed age (≥60 years),
urinary protein excretion (≥1.0 g/day), high serum crea-
tinine (≥1.0 mg/dL), and hypertension to be significant
risk factors for renal function deterioration; gender was
not related. With multivariate analysis (Table 4), urinary
excretion of protein [relative risk (RR) 4.20 (95% CI 1.14-
15.56), P = 0.032] and hypertension [RR 5.85 (95% CI
1.85-18.53), P = 0.0027] remained significantly associated
with renal function deterioration.
Among the histologic parameters tested, univariate
analysis showed that a high incidence of glomerulosclero-
sis (≥20% of total glomeruli), the severity of mesangial
proliferation (≥moderate), the area of fibrosis (≥30%
of total specimen area), a-SMA+ area (≥10% of total
specimen area), and the number of FSP1+ fibroblasts
(≥20/HPF) are all significant risk factors for renal func-
tion deterioration (Tables 2 and 3). Kaplan-Meier curves
showed that increased numbers of FSP1+ fibroblasts were
associated with diminished renal survival (Fig. 2). Indeed,
the multivariate analysis in Table 4 demonstrated that
number of FSP1+ fibroblasts [RR 7.39 (95% CI 2.15–
25.46), P = 0.00015] was the only histologic risk factor sig-
Table 2. Clinical features at the time of renal biopsy and the changes
in renal function
Changes in renal function
≥100% 1% to 99% No
Clinical features increase increase increase
Number of patients 24 48 70
Age 42.8 ± 17.3 38.3 ± 14.4 34.4 ± 13.3a
Male/female 14/10 24/24 19/51b,c
Urinary protein g/day 2.65 ± 2.11 1.05 ± 1.37d 0.99 ± 1.26d
Serum creatinine mg/dL 1.18 ± 0.26 0.92 ± 0.33d 0.74 ± 0.17d,e
Creatinine clearance 69.7 ± 36.9 77.5 ± 32.4 93.6 ± 25.9a,b
Hypertension (%) 20 (83.3) 8 (16.7)d 15 (21.4)d
Glomerulosclerosis 34.0 ± 29.6 24.1 ± 25.3 12.4 ± 16.1b,d
Area of fibrosis 32.4 ± 10.0 27.2 ± 13.8 18.2 ± 6.8d,e
a-smooth muscle 16.3 ± 10.6 9.0 ± 6.0d 7.6 ± 5.3d
actin+ area
Fibroblast-specific 23.2 ± 6.0 17.6 ± 12.1c 12.3 ± 7.2b,d
protein+ cells
Data are mean ± SD (data in parentheses are percentages of patients).
aP < 0.001 vs. ≥100% increase; bP < 0.01 vs. 1% to 99% increase; cP < 0.01
vs. ≥100% increase; dP < 0.0001 vs. ≥100% increase; eP < 0.0001 vs, 1% to 99%
increase.
nificantly associated with progression to renal loss. Three
patients with high FSP1+ cells (≥20/HPF) without any
other histologic risk factors declined to renal failure. We
also performed multivariate analysis using another end
point, which was defined as 20 mL/min decrease in the
estimated creatinine clearance from baseline (data not
shown). Estimated creatinine clearance was calculated
as described previously [26]. Among the clinical param-
eters, hypertension [RR 3.33 (95% CI 1.48–7.46), P =
0.0035] remained significantly associated with renal func-
tion deterioration. However, urinary protein excretion
(≥1.0 g/day) was not related. Among the histologic pa-
rameters, the number of FSP1+ fibroblasts [RR 5.74 (95%
CI 2.15–15.31), P = 0.0005] remained significantly asso-
ciated with deteriorating renal function.
Number of FSP1+ fibroblasts and response to
the treatments
Among 36 patients with increased FSP1+ fibroblasts
(more than 20/HPF), 16 patients were treated with
both corticosteroid and renin-angiotensin system (RAS)
antagonists and 16 patients were treated with RAS
antagonists only. Eight out of 16 patients (50%) with both
treatments declined to renal failure. Ten out of 16 patients
(62.5%) with RAS antagonists declined to renal failure.
Among 106 patients with low numbers of FSP1+ fibrob-
lasts (fewer than 20/HPF), 24 patients were treated with
both corticosteroid and RAS antagonists and 40 patients
were treated with RAS antagonists only. Two out of 24
patients (8.3%) with both treatments declined to renal
failure. Four out of 40 patients (10%) with RAS antago-
nists declined to renal failure.
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Table 3. Univariate analysis of risk factors affecting the renal survival
≥100% increase/
total patients P value
Clinical parameters
Gender
Male 14/57 0.53
Female 10/85
Age
≥60 years 6/13 0.0034
50–59 4/19 0.23
40–49 4/34 0.85
30–39 4/18 0.26
<30 6/58
Urinary excretion of protein
≥3.0 g 8/14 <0.0001
1.0–2.9 13/48 0.0014
<1.0 3/80
Serum creatinine
≥1.0 mg/dL 19/50 <0.0001
<1.0 5/92
Hypertension
(+) 20/43 <0.0001
(−) 4/99
Histologic parameters
Glomerulosclerosis
≥20% 12/49 0.019
10–19 6/25 0.051
<10 6/68
Mesangial proliferation
≥moderate 15/56 0.021
Mild to moderate 5/44 0.61
<mild 4/42
Area of fibrosis
≥30% 17/37 <0.0001
20–29 4/36 0.23
<20 3/69
a-smooth muscle actin+ area
≥20% 7/12 <0.0001
10–19 11/39 0.0007
<10 6/91
Fibroblast-specific protein 1+ cells
≥20 18/36 <0.0001
15–19 3/36 0.62
<15 3/70
DISCUSSION
Expression of FSP1 is highly specific for fibroblasts [21,
23] and enabled us for the first time to use anti-FSP1 anti-
body to identify human tissue fibroblasts in renal biopsy
specimens from patients with IgAN. Fibroblasts accumu-
lated in areas of severe interstitial fibrosis, suggesting that
they are the principal effector cells of renal fibrosis. It
was noteworthy that some of the tubular epithelial cells
surrounding the fibrotic areas also expressed FSP1. This
is because fibroblasts arise during fibrogenesis via local
EMT [22] and the FSP1+ staining of tubular epithelial
cells is consistent with this notion. FSP1 has been im-
plicated in cytoskeletal-membrane interactions, calcium
signal transduction, and cellular growth and differentia-
tion [27]. Its interaction with cytoskeletal moieties, and its
early role in EMT suggests that FSP1 may fashion mes-
enchymal cell shape and enable motility [28, 29]. Further-
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Fig. 2. Kaplan-Meier analysis of cumulative rates of renal survival
stratified into two groups on the basis of the number of fibroblast-
specific protein 1 (FSP1+) fibroblasts. Renal survival estimated on the
basis of an increase in serum creatinine to >100% above baseline levels.
Increased numbers of FSP1+ fibroblasts were associated with dimin-
ished renal survival (P < 0.0001) among those patients whose initial
serum creatinines were normal.
Table 4. Multivariate analysis of risk factors affecting the renal
survival
Relative
ratio 95% CI P value
Clinical parameters
Gender (male) 0.97 0.39–2.40 0.95
Age (≥60 years) 1.93 0.67–5.54 0.22
Urinary excretion of protein (≥1.0 g) 4.20 1.14–15.56 0.032
Serum creatinine (≥1.0 mg/dL) 2.77 0.92–8.34 0.071
Hypertension (systolic >140 or 5.85 1.85–18.53 0.0027
diastolic >90 mm Hg)
Histologic parameters
Glomerulosclerosis (≥20%) 0.76 0.32–1.80 0.53
Mesangial proliferation (≥moderate) 1.05 0.40–2.77 0.92
Area of fibrosis (≥30%) 1.72 0.59–5.03 0.32
a-smooth muscle actin+ area (≥10%) 2.78 0.88–8.77 0.082
Fibroblast-specific protein 1+ 7.39 2.15–25.46 0.0015
cells (≥20)
more, FSP1 can act as an angiogenic factor [30], and when
Ca++ dimerizes FSP1, the dimer binds the C-terminal of
p53 and alters its function [31, 32]. The expression of FSP1
indicates the presence of a molecular program determin-
ing fibroblast phenotype [33].
We also confirmed a close correlation between the
number of FSP1+ fibroblasts and serum creatinine, cre-
atinine clearance, glomerulosclerosis, and the area of fi-
brosis on the renal biopsy. Using multivariate analysis, the
number of FSP1+ fibroblasts was a significant risk factor
for progression to ESRD. Indeed, of all the parameters
tested, increased FSP1 positivity was the most predictive
determinant of eventual renal failure.
Heavy proteinuria, hypertension, and renal dysfunc-
tion have all been postulated to be risk factors for the
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progression to ESRD in IgAN patients [6–19], and we
confirmed them to be univariate risk factors in the present
study. Moreover, urinary excretion of ≥1.0 g of protein
per day and hypertension were also multivariate predic-
tors of renal function deterioration. Because we initially
excluded patients with renal insufficiency (serum creati-
nine ≥1.5 mg/dL) from the multivariate analysis, it is only
natural that high serum creatinine would not be a predic-
tor of renal function deterioration in this evaluation.
Histologic findings previously reported to be good pre-
dictors of outcome for IgAN patients include glomerular
lesions and interstitial fibrosis [6–19, 34]. In the present
study, identification of ≥20 FSP1+ fibroblasts per HPF
was a unique multivariate predictor of renal function
deterioration. It is not clear why increased Masson’s
trichrome staining of connective tissue was not a signif-
icant predictor of deteriorating renal function by multi-
variate analysis. Tissue fibroblasts are known to actively
produce fibronectin and a variety of collagens (particu-
larly types I and III), and in mice, specific reduction of
tissue fibroblasts using the thymidine kinase gene under
the control of the FSP1 promoter attenuates fibrogene-
sis, as evaluated by Masson’s trichrome staining [23]. We
suggest that because initiation and progression of fibrosis
is dependent on the number of FSP1+ fibroblasts, their
presence rather than the sampling area of fibrosis, is the
unique independent risk factor in advancing disease. In
fact, the presence of ≥20 FSP1+ fibroblasts per HPF was
indicative of a 7.39-fold increase in the risk of progression
to renal function deterioration. Figure 2 demonstrates
that increased numbers of FSP1+ fibroblasts were associ-
ated with a decreased renal survival. While the number of
FSP1+ fibroblasts (≥20/HPF) in renal tissue was the most
valuable prognostic factor for declining kidney function
in renal tissue, the area of a-SMA+ staining was not a sig-
nificant risk factor in our multivariate analysis [RR 2.78
(95% CI 0.88–8.77), P = 0.082]. Kidney sections that were
dual stained for FSP1 and a-SMA revealed that FSP1+
fibroblasts could be easily distinguished from a-SMA+
cells. We suggest, as we observed in mice with polycystic
disease [28, 35], that most of these FSP1−, a-SMA+ cells
are probably smooth muscle cells, rather than the occa-
sional myofibroblast, which would also be dual stained
[28]. This increased number of smooth muscle cells, as a
hypothesis, may derive from either decondensated blood
vessels in areas of injury and/or from delaminated en-
dothelial cells through EMT [36].
CONCLUSION
Our findings indicate immunostaining renal biopsy
specimens for FSP1+ fibroblasts may provide a valuable
histologic guide to renal progression.
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